EditorialPublished 2019
Pharmacokinetic Evaluation of Diclofenac Matrix Tablets Employing Cross Linked Starch-Urea
Abstract
ABSTRACTModified starches are promising and havinggood potential as release retardants and ratecontrolling polymers for controlled release. Thecontrolled release properties of modified starches,generally based on solvent-activation have beenintensively investigated. Aim: this aimed to researchthe in vivo performance of the new polymer (Crosslinked starch-urea or CLSU) within the formulation ofcontrolled release dosage forms. Methods: Diclofenacmatrix tablets employing CLSU were prepared bygelatinizing potato starch within the presence of ureaand salt . 15 mg strength of diclofenac matrix tablets(B) were formulated employing CLSU and pure drug(A) were tested for in vivo pharmacokinetic evolution.Plasma drug concentration of Diclofenac decided byHPLC method. From the time Vs plasmaconcentration data various pharmacokineticparameters like peak concentration (Cmax), time atwhich peak occurred (Tmax), area under the curve(AUC), elimination rate constant (kel), biological halflife(t1/2), percent absorbed to varied times andabsorption rate constant (Ka) were calculated in eachcase as per known standard methods. Results: Theabsorption rate constant (Ka) was found to be 0.152h-1 for A and 0.817 h-1 for B, and MRT was increasedfrom 9.68 h for A to 14.05 h for B. Tmax raised to 6 hfor B from 3 h for A. Based on AUC0 α the relativebioavailability of the diclofenac from CLSU wasfound to be 124.9% compared to diclofenac pure drug(100%). Conclusion: Thus the results indicated thatstarch urea cross-linked with salt may be a promisingmatrix former for controlled release.Controlled drug delivery is a topic of current interestin pharmaceutical technology and industry. In the lasttwo decades, controlled release dosage forms havemade significant progress in terms of clinical efficacyand potential compliance. Controlled release drugdelivery systems are those formulations designed torelease a lively ingredient at rates, which differsignificantly from their corresponding conventionaldosage forms. The controlled release drug deliverysystems are aimed toward controlling the speed ofdrug delivery, sustaining the duration of therapeuticactivity and / or targeting the delivery of the drug to atissue. Drug release from these systems should be at adesired rate, predictable and reproducible.The formation of cross-linked starches with calciumsalts is known in polymer chemistry. As the cross-linkedpolymers generally swell in water and aqueous fluidsand form gelatinous matrices suitable for controlledrelease, it is thought worthwhile to investigate starchurea cross linked with calcium chloride for itsapplication in controlled release.Diclofenac sodium known as diclofenac is a widely usednon-steroidal anti-inflammatory analgesic and antipyreticdrug. Controlled release formulation is neededfor diclofenac because of its short biological half-life9 of2.0 h. The drug also causes10 gastro intestinaldisturbances, peptic ulceration with bleeding if presentin large concentration in gastrointestinal tract. Hence,diclofenac is a suitable drug for oral sustained andcontrolled release and it would be advantageous to slowdown its release in gastrointestinal tract not only toprolong its therapeutic action but also to minimizepossible side effects of diclofenac.from M/s Micro Labs Ltd., Pondicherry, Methanol,Potassium dihydrogen phosphate, caustic soda , urea,salt were procured from Qualigens fine chemicals Ltd.Potato starch was procured from Loba Chemie.Crosslinked starch urea (prepared in the laboratory) andall other chemicals used in the study were of analyticalgradePreparation of Cross-linked starch urea polymer: Potatostarch (9 parts) was dispersed in purified water (10parts) to make starch slurry. Urea (1 part), salt (1 part)were dissolved in purified water (40 parts) and thereforethe solution was heated to boiling. While boiling, thestarch slurry was added and mixed. Mixing whileheating was continued for 20 minutes to form CLSUpolymer. The mass formed was spread on to a stainlesssteel plate and dried at 850C for 6-8 h. The driedpolymer was powdered and skilled mesh No. 120.Preparation of matrix Tablets: Matrix tablets of 15mgdiclofenac were prepared employing 50% CLSU. Thedrug and matrix material were mixed in mortar and thebinder, water-alcohol (1:1) solution was added and mixed thoroughly to form dough mass. The mass wasskilled mesh No.12 to get wet granules. The driedgranules were passed through mesh No.24 to breakaggregates. Passed granules were blended with talc2% and magnesium stearate 2% in a closed polythenebag. The tablets granules were compressed in totablets on rotary multi-station punching machinePharmacokinetic evaluation was done on diclofenacmatrix tablets (B) formulated employing CLSU ascompared to diclofenac pure drug (A) with a view toguage the discharge retarding and rate controllingefficiency of CLSU in vivo. When the diclofenacmatrix tablets formulated employing CLSU wereadministrated orally at the same dose of 15 mg, theplasma concentrations were found to be lower thanthose observed with the diclofenac pure drug (Fig. 1)indicating slow absorption of diclofenac from thematrix tablets. A Cmax of 2.9 ± 0.6 μg/mlwasobserved at 6.0 h following the oral administrationof matrix tablets. The absorption rate constant (Ka)was found to be 0.152 h-1 . The plasma concentrationswere stabilized and maintained within a narrow rangefor longer periods of time in the case of matrix tablets(Fig. 1). The mean duration (MRT) was increasedfrom 9.68 h for diclofenac pure drug to 14.05 h withthe matrix tablets. The MRT value indicated longerstay of drug within the body when administered asmatrix tablets. Based on AUC0 α the relativebioavailability of diclofenac from CLSU urea matrixtablets was found to be 124.9 that when compared todiclofenac pure drug (100 %). The elimination rateconstant (Kel) for diclofenac was found to be 0.1274h-1 and the corresponding half- life was found to be5.44 h following the oral administration of diclofenac.The mean residence time (MRT) was found to be 9.68h. The adsorption rate constant (Ka) was found to be0.8172 h-1 . A Cmax of 4.7 ± 1.4 μg/ml was observedat 3.0 h after oral administration of diclofenac puredrug.The pharmacokinetic evaluation, thus, indicated thatdiclofenac from the matrix tablets formulatedemploying CLSU was released slowly and absorbedslowly over longer periods of time in vivo resulting inthe maintenance of plasma concentrations within anarrow range over longer periods of time. As suchCLSU exhibited good release retarding and ratecontrolling effect in vivo in the pharmacokineticevaluation.Keywords: Diclofenac, Matrix tablets, Cross-linkedStarch-Urea, Controlled drug delivery
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Pharmaceutics & Organic Process Research
- SubjectPharmaceutical Sciences
- SubjectChemistry
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “K.P.R Chowdary”
- BylineArticles whose byline prints “Veer Reddy. K”
- BylineArticles whose byline prints “Bhaskara Reddy Nallamilli”